How did Wegovy pill sales compare with Foundayo in Q3 2026?
Novo Nordisk reported on November 4, 2026 that its semaglutide Wegovy pill generated DKK 5.39 billion in Q3 2026 sales, approximately US$813 million, compared with US$184 million for Eli Lilly’s orforglipron Foundayo. Drugnews’s November 10, 2026 analysis describes a 4.4x global revenue ratio; this compares sales across different geographic footprints.
| Measure | Reported result | Basis |
|---|---|---|
| Novo Nordisk / Wegovy pill | DKK 5.39 billion | Global sales; approximately US$813 million |
| Eli Lilly / Foundayo | US$184 million | Same quarter; geographic scope differs |
| Drugnews comparison | 4.4x | Global revenue ratio, not a clinical comparison |
Revenue does not measure head-to-head efficacy or an individual patient’s likely response.
Sources
Read the full analysis
Novo Pill Leads Lilly 4x, Lilly Takes 1/3 of Starts — 2026-11-10